The Scottish and Manchester randomised trial of neo-adjuvant chemotherapy for advanced cervical cancer.
AuthorsSymonds, R P
Reed, N S
Hunter, Robin D
Davidson, Susan E
Stewart, Alan L
AffiliationBeatson Oncology Centre, Western Infirmary, Glasgow, UK. firstname.lastname@example.org
MetadataShow full item record
Abstract204 eligible patients were entered into a multicentre randomised trial of neo-adjuvant chemotherapy prior to radical radiotherapy. The aim of this study was to assess whether there was any survival advantage in patients undergoing chemotherapy and radiotherapy compared with those given radiotherapy alone. Patients were aged up to 70 years, performance status 0-1/2, with bulky stage IIb, stage III or stage IVa squamous or adenosquamous carcinoma. Three cycles of methotrexate 100 mg/m2 and cisplatin 50 mg/m2 were given at 2-weekly intervals before radical radiotherapy. 104 eligible patients received the combination treatment and 100 radiotherapy only. The two arms of the study were well balanced for tumour and patient characteristics. The response rate to chemotherapy was 49%, 33% of patients in the radiotherapy (XRT) alone arm and 45% of the combination arm were clinically free of tumour at the end of treatment. The median follow-up for surviving patients is 5.4 years (range: 11 months-8 years) and 84% have been followed-up for more than 4 years. 134 patients have died (68 XRT only, 66 combined arm). The median survival RT alone was 111 weeks (95% confidence interval (CI) 72-151 weeks), combination arm 125 weeks (95% CI 79-170 weeks). The estimated death ratio is 0.79 (P = 0.19, 95% CI 0.56-1.12). The estimated 3-year survival is 40% (95% CI 30-50%) RT only compared with 47% (95% CI 37-57%) in the combination arm. Acute and late toxicity of radiotherapy was not increased by the addition of chemotherapy.
CitationThe Scottish and Manchester randomised trial of neo-adjuvant chemotherapy for advanced cervical cancer. 2000, 36 (8):994-1001 Eur. J. Cancer
JournalEuropean Journal of Cancer
- Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01.
- Authors: Eifel PJ, Winter K, Morris M, Levenback C, Grigsby PW, Cooper J, Rotman M, Gershenson D, Mutch DG
- Issue date: 2004 Mar 1
- A feasibility study of topotecan with standard-dose cisplatin and concurrent primary radiation therapy in locally advanced cervical cancer.
- Authors: Gatcliffe TA, Tewari KS, Shah A, Brewster WR, Burger RA, Kuo JV, Monk BJ
- Issue date: 2009 Jan
- Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervix: a randomized trial.
- Authors: Lorvidhaya V, Chitapanarux I, Sangruchi S, Lertsanguansinchai P, Kongthanarat Y, Tangkaratt S, Visetsiri E
- Issue date: 2003 Apr 1
- Randomized study comparing chemotherapy plus radiotherapy versus radiotherapy alone in FIGO stage IIB-III cervical carcinoma. GONO (North-West Oncologic Cooperative Group).
- Authors: Chiara S, Bruzzone M, Merlini L, Bruzzi P, Rosso R, Franzone P, Orsatti M, Vitale V, Foglia G, Odicino F
- Issue date: 1994 Aug
- [Randomized trial of initial chemotherapy in 151 locally advanced carcinoma of the cervix (T2b-N1, T3b, MO)].
- Authors: Chauvergne J, Rohart J, Héron JF, Aymé Y, Berlié J, Fargeot P, George M, Lebrun-Jezekova D, Pigneux J, Chenal C
- Issue date: 1990